Opt-out screening tripled chlamydia and gonorrhoea testing among teens in US primary care
- Children's Hospital of Philadelphia changed how 33 primary care practices screen adolescents for chlamydia and gonorrhoea.
- Screening among sexually active teens rose to 75% from 25% in girls and from 20% in boys between 2021 and 2025.
- Universal opt-out screening, in which all eligible teens are tested unless they decline, brought the biggest gains.
- More infections were found, and improvements were seen across insurance types and ethnic groups.
Chlamydia and gonorrhoea are common bacterial sexually transmitted infections. Most cause no symptoms and are often missed without screening, and people aged 15 to 24 account for about half of new STIs in the United States. Yet many adolescents are not screened, and fewer than one third are asked about sexual activity at their check-ups.
What CHOP changed
Researchers at Children's Hospital of Philadelphia (CHOP), publishing in the journal Pediatrics, describe a quality improvement programme introduced in stages across 33 primary care practices. It started with a pre-visit Adolescent Health Questionnaire, then added electronic health record alerts, pre-filled order sets and incentives for clinicians. The last step was universal opt-out screening: every eligible adolescent is tested unless they decline.
Also read: Screening twice for STIs in pregnancy linked to fewer preterm births in randomised trial
The results
- Between 2021 and 2025, screening among sexually active girls rose from 25% to 75%, and among sexually active boys from 20% to 75%.
- Infections detected in girls rose from about 8 to about 25 a month at the busiest testing period, and in boys from 4 to 16 a month.
- Gains were seen across insurance types and racial and ethnic groups.
Lead author Dr. Brian Jenssen said the move from risk-based to universal opt-out screening appears to have made the biggest difference, and that the approach can be adapted by other primary care practices.
Limits
This was a quality improvement study within one US paediatric network, not a randomised trial, so results elsewhere may differ.
Source: News-Medical (Children's Hospital of Philadelphia)
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What is opt-out STI screening for adolescents?
Opt-out STI screening means every eligible adolescent is tested for infections such as chlamydia and gonorrhoea unless they decline the test.
How much did chlamydia and gonorrhoea screening increase at CHOP?
At CHOP practices, screening rose from 25% to 75% among sexually active girls and from 20% to 75% among sexually active boys between 2021 and 2025.
Why is chlamydia and gonorrhoea screening important for teenagers?
Chlamydia and gonorrhoea usually cause no symptoms, and young people aged 15 to 24 account for about half of new STIs in the United States, so screening finds infections that would otherwise be missed.
Did the CHOP screening programme find more infections?
Yes, the CHOP screening programme detected more infections: in girls from about 8 to about 25 cases a month at peak testing, and in boys from 4 to 16 a month.
Where was the CHOP adolescent screening study published?
The CHOP adolescent chlamydia and gonorrhoea screening study was published in the journal Pediatrics.



